Table 3.

Plasma total IGF-I and IGFBP-3, and IGF-I/IGFBP-3 ratio (mean ± SD) at baseline and after treatment with pegvisomant or octreotide

BiomarkerTreatment
Pegvisomant (mg/d ×14 d)
Octreotide (μg TID ×14 d)
406080200
Total IGF-I
    Baseline (ng/mL)169 ± 46189 ± 44165 ± 45160 ± 59
    Nadir during treatment (ng/mL)71 ± 1775 ± 2061 ± 16102 ± 32
    Maximum suppression (%)57 ± 960 ± 762 ± 936 ± 16
    Duration of suppression (days after the last dose)>35>35>35∼7
IGFBP-3
    Baseline (ng/mL)2,161 ± 4542,169 ± 3112,043 ± 3351,942 ± 516
    Day 14 (ng/mL)1,415 ± 3071,430 ± 2351,177 ± 2171,702 ± 441
Total IGF-I/IGFBP-3 ratio
    Baseline (ng/mL)0.082 ± 0.0260.086 ± 0.0140.081 ± 0.0180.086 ± 0.026
    Day 14 (ng/mL)0.059 ± 0.0140.062 ± 0.0140.064 ± 0.0150.078 ± 0.034